Pricing Log in Create free account
Friday 6 November 2026 Export JAZZ’s income statement to Excel — free account

Jazz Pharmaceuticals PLC

JAZZ Healthcare Biotechnology

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.

Revenue
+10.4%
EPS
−280.5%
Free cash flow
−60.4%
Total debt
+3.88%

Quarter to September 2026, against a year earlier

235.25 7.93 +3.49%
Market cap
$14.6B
P/E
64.7×
Fwd P/E
35.9×
Dividend yield
—
F-score
5/9
Altman Z
1.37
Beneish M
−3.03
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Jazz Pharmaceuticals PLC 10-K filed Feb 24, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:10 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 26, 2025: 40 added · 25 removed · 118 modified; 7 with only figures updated; 2 moved without change

  1. Modified · Overview

    Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases -rare disease – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disordersaddressing epilepsies, cancers and epilepsy, and a growing portfolio of cancer treatmentssleep disorders. Our patient-focused and science-driven approach powers pioneering research and development R&D advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience.